Hemophilia A
Conditions
Keywords
safety, immunogenicity, hemostatic efficacy, prophylactic, infants, children, hemostasis, hemophilia
Brief summary
This study prospectively investigates the safety, FVIII immunogenicity, and hemostatic efficacy of prophylactic HEMLIBRA® given with a concomitant low dose recombinant factor VIII (rFVIII) known as NUWIQ®, in HA infants and children \<3 years old who have had little to no previous exposure to FVIII. In addition, the study investigates the safety and efficacy of a novel FVIII ITI regimen in children \<21 with existing low and high titer inhibitors (LTI and HTI).
Detailed description
Hemophilia A (HA) is a congenital bleeding disorder caused by deficient or dysfunctional factor VIII (FVIII) which leads to bleeding correlated with severity. Management is focused on FVIII replacement in reaction to a bleed or preventive as prophylaxis. Effective treatment is complicated by the: (1) difficulty to administer standard replacement therapy via intravenous injection especially in infants and young children; and (2) development of inhibitors (FVIII neutralizing antibodies). Inhibitors can increase morbidity and mortality and exponentially raise the cost of health care. Although inherited and environmental risk factors for inhibitor formation have been identified, there is no effective strategy to prevent inhibitors from developing. Emicizumab (HEMLIBRA®) was recently approved by the Food and Drug Administration (FDA) in infants, children, and adults with congenital hemophilia A, with and without inhibitors, and offers hemostatic efficacy while reducing the burden of administration since it is given weekly, biweekly (every 2 weeks), or monthly via subcutaneous (SQ) route compared to the intravenous (IV) route of FVIII. This study prospectively investigates the safety, FVIII immunogenicity, and hemostatic efficacy of prophylactic HEMLIBRA® given with a concomitant low dose recombinant factor VIII (rFVIII) known as NUWIQ®, in HA infants and children \<3 years old who have had little to no previous exposure to FVIII. In addition, the study investigates the safety and efficacy of a novel FVIII ITI regimen in children \<21 with existing low and high titer inhibitors (LTI and HTI).
Interventions
DRUGNuwiq (low dose protocol)
After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
DRUGHEMLIBRA
Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
DRUGNuwiq (Atlanta protocol)
After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
Sponsors
Genentech, Inc.
Emory University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
- Part A: * Moderately severe (≤2% FVIII) hemophilia A * \<3 Years of age at the time of informed consent * Caregiver (parent or legal guardian) has provided written informed consent * ≤2 EDs to pdFVIII, rFVIII, or a single dose of FFP, Cryoprecipitate or PRBCs. * Adequate hematologic function (HgB \>8 g/dL and platelet count \>100,000 µL) * Adequate hepatic function (total bilirubin ≤1.5x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's) * Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min) * Negative test for inhibitor (\<0.6 BU/mL) with a 72-hour washout within 4 weeks of enrollment * No documented FVIII inhibitor since birth \*Participants will be encouraged to co-enroll in the ATHN 8 Study Inclusion Criteria - Part B * Moderately severe (≤2% FVIII) hemophilia A * \<21 Years of age at the time of informed consent * Documented on 2 occasions a persistent low (\>0.6 BU/mL) titer inhibitor with a 72-hour washout within 24 weeks of enrollment or historical high titer inhibitor (\>5 BU/mL) and a single occasion of a low titer inhibitor (\>0.6 BU/mL) with a 72-hour washout within 24 weeks of enrollment after either the first time ITI or after single attempt of \<6 months of continuous 3x/week factor ITI * Has completed loading doses of HEMLIBRA® (weekly for 4 weeks, dose 3 mg/kg, a total of 12 mg/kg/dose will also be allowed) * Caregiver and/or participant provided written informed consent * Adequate hematologic function (HgB \>8 g/dL and platelet count \>100,000 µL) * Adequate hepatic function (total bilirubin ≤1.5x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's) * Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min)
Exclusion criteria
- Part A and B * Inherited or acquired bleeding disorder other than severe hemophilia A (participants with previous documentation of low von Willebrand factor (vWF) defined as vWF antigen and vWF ristocetin cofactor both between 40-50 will be permitted) * Previous or current treatment for thromboembolic disease or signs of thromboembolic disease * Conditions that may increase the risk of bleeding or thrombosis. Will not require or request a thrombophilia evaluation * History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the HEMLIBRA® injection (with the exception of rituximab) * Known HIV infection with CD4 count \<200 cells/µL within 24 weeks prior to screening. Testing is not required if can demonstrate negative testing in the mother prior to pregnancy * Use of systemic immunomodulators at enrollment or planned use during the study * Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment * Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose an additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study * Planned surgery (excluding minor procedures or central line placement) during the study * Receipt of HEMLIBRA® as part of a prior investigational study; an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of the last drug administration; a non-hemophilia-related investigational drug concurrently, within the last 30 days or 5 half-lives, whichever is shorter
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative incidence of inhibitors to FVIII | Duration of the follow up (up to 36 months) | Cumulative incidence of inhibitors to FVIII will be recorded |
| Number of Immune Tolerance Induction (ITI) success cases | Duration of the follow up (up to 36 months) | ITI success case is confirmed if three of below are criteria met: 1. Inhibitor titre \< 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection 3. Half-life of FVIII ≥ 6 h |
| Number of Immune Tolerance Induction (ITI) partial success cases | Duration of the follow up (up to 36 months) | ITI partial success case is confirmed if two of below criteria are met: 1. Inhibitor titre \< 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection 3. Half-life of FVIII ≥ 6 h |
| Number of Immune Tolerance Induction (ITI) partial response cases | Duration of the follow up (up to 36 months) | ITI partial response case is confirmed if one of below criteria is met: 1. Inhibitor titre \< 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection 3. Half-life of FVIII ≥ 6 h |
| Number of Immune Tolerance Induction (ITI) partial failure cases | Duration of the follow up (up to 36 months) | ITI partial failure case is confirmed if none of below criteria are met, but participant who initially had a high-titre inhibitor (≥ 5 BU/mL) has a low-titre inhibitor (\< 5 BU/mL) at end of ITI. 1. Inhibitor titre \< 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection 3. Half-life of FVIII ≥ 6 h |
| Number of Immune Tolerance Induction (ITI) failure cases | Duration of the follow up (up to 36 months) | ITI failure case is confirmed if none of below criteria are met: 1. Inhibitor titre \< 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection 3. Half-life of FVIII ≥ 6 h |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of infusions of Nuwiq/Novo7 for treatment of an acute bleeding episode | Duration of the follow up (up to 36 months) | Number of infusions of Nuwiq/Novo7 for treatment of an acute bleeding episode will be recorded |
| Number of infusions of rFVIII or rFVIIa for treatment of an acute bleeding episode | Duration of the follow up (up to 36 months) | Number of infusions of rFVIII or rFVIIa for treatment of an acute bleeding episode will be recorded |
| Change in blood levels of emicizumab (HEMLIBRA®) in young children (1 month to 24 months of age) | Weekly for 4 weeks, monthly for 5 months, and every 3 months until study end (up to 36 months) | Blood levels of emicizumab (HEMLIBRA®) in young children (1 month to 24 months of age) will be measured to study Emicizumab pharmacokinetics |
| Number of joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks) | 6 months follow up | Number of joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks) will be recorded |
| Change in CATCH scale score | Baseline, 36 months | Scores are calculated as the mean of scores for all items, if 50% or more of the items are missing, then the score is set at missing. CATCH scores range from 0 to 100, with the following interpretation: * Higher score = Higher the perceived risk to have a bleed while doing daily activities * Higher score = Higher impact of hemophilia on daily activities * Higher score = Higher the perceived risk to have a bleed while doing social activities * Higher score = Higher impact of hemophilia on social activities * Higher score = Higher the perceived risk to have a bleed while doing recreational activities * Higher score = Higher impact of hemophilia on recreational activities * Higher score = Higher impact of hemophilia on work/school activities * Higher score = Greater preoccupation related to hemophilia * Higher score = Greater perceived burden of the hemophilia treatment |
| Change in Adapted Inhib-QoL scale score | Baseline, 36 months | Adapted Inhib-QoL scores range from 0 to 100, with lower scores reflecting better health-related quality of life |
| Microbiota composition of stool in infants with vs. without inhibitors | Duration of the follow up (up to 36 months) | Microbiota composition of stool in infants with vs. without inhibitors will be measured |
| Number of target joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks) | 12 months follow up | Number of target joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks) will be recorded |
| Annualized bleeding rate (ABR) | Duration of the follow up (up to 36 months) | Number of bleeding events over time (bleed rate) will be recorded to calculate ABR to determine hemostatic efficacy of treatment regiments. Annualized bleeding rate (bleeds/year) is calculated as the number of bleeding events divided by length of time of the treatment regimen. |
| Number of adverse events | Duration of the follow up (up to 36 months) | Number of adverse events (AEs and SAEs) will be recorded to evaluate safety of treatment regiments |
| Change in blood levels of anti-FVIII antibodies | Weekly x4 (±3 days), then monthly (±7 days) up to 36 months | Blood test will be done to evaluate blood levels of anti-FVIII antibodies |
| Change in blood levels of anti-Emicizumab antibodies | Weekly x4 (±3 days), then monthly (±7 days) up to 36 months | Blood test will be done to evaluate blood levels of anti-Emicizumab antibodies |
Countries
United States
Outcome results
None listed